Prosecution Insights
Prosecution Insights
6 pending office actions • 5 art units • 5 examiners • 0 of 6 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (17%) |
| §103 only | 3 (50%) |
| §112 only | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LIU, TRACY | 2 | 54.9% | +28.0% |
| AEDER, SEAN E | 1 | 56.9% | +19.6% |
| MCCOLLUM, ANDREA K | 1 | 60.7% | +32.1% |
| KASSA, TIGABU | 1 | 36.5% | +28.6% |
| NGUYEN, QUANG | 1 | 38.2% | +52.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18365369 | Method for Determining Prognosis of Cancer | AEDER, SEAN E | 3d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17953674 | Dental Compositions | LIU, TRACY | 79d overdue |
| 18344502 | ROR2 INHIBITORS AND USE THEREOF IN TREATING AND/OR PREVENTING CARTILAGE LOSS | MCCOLLUM, ANDREA K | 73d overdue |
| 18268933 | Composition Comprising Calcium Orthophosphate and a Bioactive Glass Comprising Fluorine | LIU, TRACY | 38d overdue |
| 18256752 | SUSTAINED RELEASE FORMULATIONS OF CRYSTALLINE DRUGS | KASSA, TIGABU | 8d overdue |
| 18365369 | Method for Determining Prognosis of Cancer | AEDER, SEAN E | 3d overdue |
| 18156184 | Oncolytic Vaccinia Virus | NGUYEN, QUANG | 20d |
| Art Unit | Apps |
|---|---|
| 1614 | 2 |
| 1642 | 1 |
| 1674 | 1 |
| 1619 | 1 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18365369 | Method for Determining Prognosis of Cancer | AEDER, SEAN E | 1642 | §101 | Non-Final OA | 3d overdue | Pending | Aug 04, 2023 |
| 18344502 | ROR2 INHIBITORS AND USE THEREOF IN TREATING AND/OR PREVENTING CARTILAGE LOSS | MCCOLLUM, ANDREA K | 1674 | §112 | Final Rejection | 73d overdue | Pending | Jun 29, 2023 |
| 18268933 | Composition Comprising Calcium Orthophosphate and a Bioactive Glass Comprising Fluorine | LIU, TRACY | 1614 | §103 | Final Rejection | 38d overdue | Pending | Jun 21, 2023 |
| 18256752 | SUSTAINED RELEASE FORMULATIONS OF CRYSTALLINE DRUGS | KASSA, TIGABU | 1619 | §103 | Non-Final OA | 8d overdue | Pending | Jun 09, 2023 |
| 18156184 | Oncolytic Vaccinia Virus | NGUYEN, QUANG | 1631 | §112 | Final Rejection | 20d | Pending | Jan 18, 2023 |
| 17953674 | Dental Compositions | LIU, TRACY | 1614 | §103 | Final Rejection | 79d overdue | Pending | Sep 27, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial